Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its holdings in Galectin Therapeutics Inc. (NASDAQ:GALT) by 19.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 50,826 shares of the company’s stock after acquiring an additional 8,105 shares during the quarter. Bank of New York Mellon Corp owned 0.08% of Galectin Therapeutics worth $66,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Barclays PLC boosted its stake in Galectin Therapeutics by 309.0% in the 3rd quarter. Barclays PLC now owns 28,587 shares of the company’s stock worth $79,000 after purchasing an additional 21,598 shares in the last quarter. Stratos Wealth Partners LTD. increased its stake in Galectin Therapeutics by 27.4% during the 4th quarter. Stratos Wealth Partners LTD. now owns 51,550 shares of the company’s stock valued at $66,000 after purchasing an additional 11,100 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Galectin Therapeutics by 2.5% in the third quarter. Geode Capital Management LLC now owns 862,542 shares of the company’s stock worth $2,372,000 after buying an additional 20,817 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Galectin Therapeutics by 46.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,369 shares of the company’s stock worth $66,000 after buying an additional 16,271 shares during the period. Finally, State Street Corp grew its holdings in shares of Galectin Therapeutics by 9.3% during the third quarter. State Street Corp now owns 251,014 shares of the company’s stock valued at $690,000 after buying an additional 21,399 shares during the last quarter. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Stock Performance

NASDAQ GALT opened at $1.52 on Monday. The firm has a market capitalization of $95.40 million, a P/E ratio of -2.08 and a beta of 0.69. The stock has a 50-day simple moving average of $1.45 and a two-hundred day simple moving average of $1.98. Galectin Therapeutics Inc. has a fifty-two week low of $0.73 and a fifty-two week high of $4.27.

Wall Street Analysts Forecast Growth

GALT has been the subject of a number of research analyst reports. HC Wainwright restated a “neutral” rating on shares of Galectin Therapeutics in a research note on Friday, December 27th. StockNews.com downgraded shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 30th.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.